US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Biofrontera AG (0DOL) 銘柄情報

Biofrontera AG (0DOL)

2.875

0.00

(0.00%)

終了 7月11日 12:30AM

Biofrontera AG (0DOL) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

2.875

( - )

買値

2.805

売値

2.945

出来高

4

平均取引量 (3 か月)

1,415 €

財務取引量

-

0.00 日の範囲 0.00

2.875 52 週間の範囲 2.875

時価総額

企業価値

10.533M

前日終値

2.875

始値

-

時刻

最終取引時間

VWAP

-

歳入

13.63M

純利益

-2.44M

発行済株式数

6,076,862

浮動株比率 (%)

23.00%

機関投資家保有比率 (%)

42.62%

配当利回り

PER

-2.13

株価売上高倍率 (PSR)

1.05

1 株当たり利益 (EPS)

-0.4

ベータ

-0.24

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the tr... Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany. 詳細を表示

セクター

Health Care

業界

-

ウェブサイト

www.biofrontera.com

本社

Leverkusen, Germany

設立

1997

Biofrontera AG is listed in the Health Care sector of the ロンドン証券取引所 with ticker 0DOL. The last closing price for Biofrontera was 2.88 €. Over the last year, Biofrontera shares have traded in a share price range of 2.875 € to 2.875 €.

Biofrontera currently has 6,076,862 shares in issue. The market capitalisation of Biofrontera is 17.47 € million. Biofrontera has a price to earnings ratio (PE ratio) of -2.13.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	2.875	2.875	2.875	0	0	DE
52	0	0	2.875	2.875	2.875	0	2.875	DE
156	0	0	2.875	60.375	2.875	0	2.875	DE
260	0	0	2.875	60.375	2.875	5	2.875	DE

0DOL - Frequently Asked Questions (FAQ)

What is the current Biofrontera AG share price?

The current share price of Biofrontera AG is 2.875 €

How many Biofrontera AG shares are in issue?

Biofrontera AG has 6,076,862 shares in issue

What is the market cap of Biofrontera AG?

The market capitalisation of Biofrontera AG is EUR 17.47M

What is the 1 year trading range for Biofrontera AG share price?

Biofrontera AG has traded in the range of 2.875 € to 2.875 € during the past year

What is the PE ratio of Biofrontera AG?

The price to earnings ratio of Biofrontera AG is -2.13

What is the cash to sales ratio of Biofrontera AG?

The cash to sales ratio of Biofrontera AG is 1.05

What is the registered address of Biofrontera AG?

The registered address for Biofrontera AG is Hemmelrather Weg 201, Leverkusen, North Rhine-Westphalia, 51377

What is the Biofrontera AG website address?

The website address for Biofrontera AG is www.biofrontera.com

i_like_bb_stock

i_like_bb_stock 3分前

i_like_bb_stock

i_like_bb_stock 3分前

I’ll take it gotta do some digging this weekend

oldstocks

oldstocks 4分前

Can you cite any court records, regulatory filings, press releases, or other evidence to support the suggestion that Dilan Gonzalez or Cade Carter are facing legal charges.

This is a serious allegation, and without supporting evidence it should be treated as an unsupported rumor.

i_like_bb_stock

i_like_bb_stock 4分前

Boing x 2

Boing x 2 4分前

It appears that we might be close to an end of selling and making a bottom.

Jul 10, 2026 3.8300 3.8700 3.7800 3.8500 3.8500 11,632,400
Jul 9, 2026 3.8600 3.9000 3.8000 3.8600 3.8600 15,737,700
Jul 8, 2026 3.8600 3.8800 3.7000 3.7800 3.7800 30,854,800

Gold

pdicamillo1

pdicamillo1 4分前

And I think we should discuss the risk of non-consensual DNA collection with these different oral fluid drug detection devices. This topic is way over my head so I did ask Gemini to explain it further:

And if anyone else has further insight please feel free to add some knowledge. Fe

RRP60

I will take back my earlier rant. Mhra and fda are the agencies working on the highest integrity out there. I should not blame them, just because my application is not yet processed in my favor. If there is a negative decision, i will respect it and ask the company to rectify it if possible and refi

Denn55

There could be for sure. I hope they find out that its worth saving and the decide to start drilling. We just dont know at this point.

theorysuit

theorysuit 6分前

Going on 3 years since submission is the tell. Nwbo desperate to keep the charade alive. Need to dilute more and keep the scamco alive......what are the next carrots for delay from the pump crew....

nonesuch2

nonesuch2 6分前

Spew all ya want. Doesn’t change anything!

learningcurve2020

learningcurve2020 8分前

But what about the mature CDMO? How’s it possible the company hasn’t even PR’d one new customer that could pull poor shareholders out of this dive? Or even mention the CDMO on their website? 🤷‍♀️

NotTheRealBeeny

NotTheRealBeeny 9分前

🤣 we'll talk soon.

manibiotech

manibiotech 10分前

Good find
It very well could be .

ErnieBilco

ErnieBilco 11分前

This is my biggest concern as it would place us right back to pre-RS valuations which means the company has gotten ZERO appreciation since the RS was done. Very sad to think about it that way but numbers mean more to me than words.

Downside case becomes more probable, not just possib

Red_Right_Hand

Red_Right_Hand 13分前

Becky Willoughby is a consultant of NWBO's and was acknowledged on the last slide of the BNOS slide deck. She posted this on LinkedIn about 2 weeks ago.

Any thoughts on whether her post has anything to do with her experience with NW, and with the Advent acquisition last fall? Could so

2latefortears

2latefortears 13分前

https://x.com/tylerehand/status/2075775265012154834?s=46&t=PY6cZdqw8iKtHPNq2RbYQw

2latefortears

2latefortears 13分前

https://x.com/tylerehand/status/2075775265012154834?s=46&t=PY6cZdqw8iKtHPNq2RbYQw

learningcurve2020

learningcurve2020 14分前

Appreciate your willingness to correct yourself, Goats. It’s something rarely seen here.

TenKay

TenKay 16分前

Greg Hopkins is a front for Brian Foote to allow this type of nonsense. Foote is the controlling shareholder of RWAX. It’s his show.

quester614

quester614 17分前

So I took a quick look at UMAV. I didn't have to go back very far to see that this 6 year old OTC Co. is on it's last breath. So now after all the other failures (HALO, Nano Lubes, Retacell, TF 600) Duffy signs a MOU with UMAV and 6 years ago they sold for about .20 with a SMALL OS of LESS than 5 mi

LarryBear40

LarryBear40 17分前

I'd doubt very seriously if the quarterlies are audited.

WooptdooU

WooptdooU 17分前

We hhpls are twice burned when you look at the shear volume of direct company DILUTION and INSIDER SELLS during each run up (using different tactics, motives and vehicles), just STAGGERING amount of personal wealth created for the GRIFTERS themselves WITHOUT any true success.
Some say pure S

rmoss

And remind me the OS I think is 6 bil plus.
How fast anyone think the price will move unless they do a buy back which Brian Foote
Has may times hinted buy backs that never happened not in rwax but other tickers or he may have here can't remember. Or they cancel out shares WHICH Bria

learningcurve2020

learningcurve2020 18分前

You’re using someone aligned with NWBO as your one example. LOL.

biotech_researcher

biotech_researcher 18分前

“Because, dcvax methodology is elegant enough to convince the experts…”
I see…..

Golden Arrow Resources

Ci Canadian Dividend Fun...

Cellectis Nom Eo 05

DJ US Building Materials...

2.375% 25sep2026

Bnp Paribas Easy Equity ...

Slantse Tobacco Internat...

FTSE EDHEC Risk Efficien...

1.625% Nts 02/06/28 144a

HSBC Securities Services...

Autozone Inc Dl 01

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。